Cargando…
Clinical Utility of Serum Autoantibodies Detected by Protein Microarray in Melanoma
Better prognostic and predictive markers in melanoma are needed to select patients for therapy. We utilized a dual-lectin affinity chromatography and a natural protein microarray-based analysis to select a subproteome of target glycoproteins to profile serum antibodies against melanoma associated an...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3199061/ https://www.ncbi.nlm.nih.gov/pubmed/22084687 http://dx.doi.org/10.1155/2011/413742 |
_version_ | 1782214522026590208 |
---|---|
author | Sabel, Michael S. Liu, Yashu Griffith, Kent A. He, Jintang Xie, Xaiolei Lubman, David M. |
author_facet | Sabel, Michael S. Liu, Yashu Griffith, Kent A. He, Jintang Xie, Xaiolei Lubman, David M. |
author_sort | Sabel, Michael S. |
collection | PubMed |
description | Better prognostic and predictive markers in melanoma are needed to select patients for therapy. We utilized a dual-lectin affinity chromatography and a natural protein microarray-based analysis to select a subproteome of target glycoproteins to profile serum antibodies against melanoma associated antigens that may predict nodal positivity. We identified 5 melanoma-associated antigens using this microarray coupled to mass spectrometry; GRP75, GRP94, ASAH1, CTSD and LDHB. We evaluated their predictive value for nodal status adjusting for age, gender, Breslow thickness, mitotic rate and ulceration using standard logistic regression. After adjustment, ASAH1, CTSD and LDHB were significantly negatively associated with nodal status (P = 0.0008) and GRP94 was significantly positively associated (P = 0.014). Our best multivariate model for nodal positivity included Breslow thickness, presence of serum anti-ASAH1, anti-LDHB or anti-CTSD, and presence of serum anti-GRP94, with an area under the ROC curve of 0.869. If validated, these results show promise for selecting clinically node negative patients for SLN biopsy. In addition, there is strong potential for glycoprotein microarray to screen serum autoantibodies that may identify patients at high risk of distant metastases or those likely or unlikely to respond to treatment, and these proteins may serve as targets for intervention. |
format | Online Article Text |
id | pubmed-3199061 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-31990612011-11-14 Clinical Utility of Serum Autoantibodies Detected by Protein Microarray in Melanoma Sabel, Michael S. Liu, Yashu Griffith, Kent A. He, Jintang Xie, Xaiolei Lubman, David M. Int J Proteomics Research Article Better prognostic and predictive markers in melanoma are needed to select patients for therapy. We utilized a dual-lectin affinity chromatography and a natural protein microarray-based analysis to select a subproteome of target glycoproteins to profile serum antibodies against melanoma associated antigens that may predict nodal positivity. We identified 5 melanoma-associated antigens using this microarray coupled to mass spectrometry; GRP75, GRP94, ASAH1, CTSD and LDHB. We evaluated their predictive value for nodal status adjusting for age, gender, Breslow thickness, mitotic rate and ulceration using standard logistic regression. After adjustment, ASAH1, CTSD and LDHB were significantly negatively associated with nodal status (P = 0.0008) and GRP94 was significantly positively associated (P = 0.014). Our best multivariate model for nodal positivity included Breslow thickness, presence of serum anti-ASAH1, anti-LDHB or anti-CTSD, and presence of serum anti-GRP94, with an area under the ROC curve of 0.869. If validated, these results show promise for selecting clinically node negative patients for SLN biopsy. In addition, there is strong potential for glycoprotein microarray to screen serum autoantibodies that may identify patients at high risk of distant metastases or those likely or unlikely to respond to treatment, and these proteins may serve as targets for intervention. Hindawi Publishing Corporation 2011 2011-10-19 /pmc/articles/PMC3199061/ /pubmed/22084687 http://dx.doi.org/10.1155/2011/413742 Text en Copyright © 2011 Michael S. Sabel et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Sabel, Michael S. Liu, Yashu Griffith, Kent A. He, Jintang Xie, Xaiolei Lubman, David M. Clinical Utility of Serum Autoantibodies Detected by Protein Microarray in Melanoma |
title | Clinical Utility of Serum Autoantibodies Detected by Protein Microarray in Melanoma |
title_full | Clinical Utility of Serum Autoantibodies Detected by Protein Microarray in Melanoma |
title_fullStr | Clinical Utility of Serum Autoantibodies Detected by Protein Microarray in Melanoma |
title_full_unstemmed | Clinical Utility of Serum Autoantibodies Detected by Protein Microarray in Melanoma |
title_short | Clinical Utility of Serum Autoantibodies Detected by Protein Microarray in Melanoma |
title_sort | clinical utility of serum autoantibodies detected by protein microarray in melanoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3199061/ https://www.ncbi.nlm.nih.gov/pubmed/22084687 http://dx.doi.org/10.1155/2011/413742 |
work_keys_str_mv | AT sabelmichaels clinicalutilityofserumautoantibodiesdetectedbyproteinmicroarrayinmelanoma AT liuyashu clinicalutilityofserumautoantibodiesdetectedbyproteinmicroarrayinmelanoma AT griffithkenta clinicalutilityofserumautoantibodiesdetectedbyproteinmicroarrayinmelanoma AT hejintang clinicalutilityofserumautoantibodiesdetectedbyproteinmicroarrayinmelanoma AT xiexaiolei clinicalutilityofserumautoantibodiesdetectedbyproteinmicroarrayinmelanoma AT lubmandavidm clinicalutilityofserumautoantibodiesdetectedbyproteinmicroarrayinmelanoma |